NEW YORK (GenomeWeb) – Genomics England said today that it has selected Icon, a provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries, as its data management partner for the 100,000 Genomes Project.
Specifically, Icon will use its data management capabilities and its clinical trials expertise to validate clinical data from 70,000 cancer and rare disease patients and their families who are participating in the UK-led effort.
"We are very proud that our genomics knowledge and our capabilities in securely managing large clinical and real world datasets have been chosen by Genomics England for such an important and transformative project," Brendan Buckley, Icon's chief medical officer, said in a statement. James Peach, Genomics England's managing director for the 100K Genomes Project main program, added that Icon's expertise in data management "will be fundamental in driving scientific research and accelerating the return of results for NHS patients."
Genomics England also has agreements with a number of bioinformatics companies to provide clinical genome interpretation for the project.